Page last updated: 2024-11-07

5-acetylamino-6-formylamino-3-methyluracil

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

5-acetylamino-6-formylamino-3-methyluracil: metabolite of caffeine [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID108214
CHEBI ID32643
SCHEMBL ID1393668
MeSH IDM0111537

Synonyms (19)

Synonym
n-(6-formamido-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)acetamide
afmu
5-acetylamino-6-formylamino-3-methyluracil
85438-96-6
5-acetamido-6-formamido-3-methyluracil
CHEBI:32643 ,
FT-0661140
n-(6-formamido-3-methyl-2,4-dioxo-1h-pyrimidin-5-yl)acetamide
n-(4-(formylamino)-1,2,3,6-tetrahydro-1-methyl-2,6-dioxo-5-pyrimidinyl)acetamide
acetamide, n-(4-(formylamino)-1,2,3,6-tetrahydro-1-methyl-2,6-dioxo-5-pyrimidinyl)-
lqw8yau3vf ,
unii-lqw8yau3vf
AB07631
DTXSID20234663
SCHEMBL1393668
(also see a168213)
FT-0661141
Q27115033
A935783

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" After drug-induced hepatitis, a caffeine test might be used to check the total recovery or to choose an adapted dosage of medicines."( Caffeine metabolism differences in acute hepatitis of viral and drug origin.
Bechtel, PR; Bechtel, YC; Brientini, MP; David-Laroche, M; Lelouët, H; Miguet, JP; Paintaud, G,
)
0.13
"Any sampling interval at least 4 h after caffeine dosing is suitable for NAT2 and XO activity assessments."( Phenotyping of N-acetyltransferase type 2 and xanthine oxidase with caffeine: when should urine samples be collected?
Fuhr, U; Jetter, A; Kinzig, M; Rodamer, M; Sörgel, F; Tomalik-Scharte, D, 2009
)
0.35
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
formamidopyrimidine
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (3)

PathwayProteinsCompounds
Caffeine Pathway, Pharmacokinetics66
Caffeine Metabolism821
Caffeine and theobromine metabolism011

Research

Studies (48)

TimeframeStudies, This Drug (%)All Drugs %
pre-199012 (25.00)18.7374
1990's16 (33.33)18.2507
2000's15 (31.25)29.6817
2010's4 (8.33)24.3611
2020's1 (2.08)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 17.98

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index17.98 (24.57)
Research Supply Index4.03 (2.92)
Research Growth Index4.38 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (17.98)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (3.77%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other51 (96.23%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]